India, July 18 -- Telomir Pharmaceuticals, Inc. (TELO) surged 90.08 percent to $2.30 on Friday after announcing promising preclinical results for its lead candidate, Telomir-1.
TELO opened at $3.05 and traded between $2.04 and $3.10, with volume skyrocketing to 116.5 million shares compared to an average of 600,831 on the Nasdaq. The stock's 52-week range is $1.12 to $8.40, and its previous close was $1.21.
The study demonstrated that Telomir-1 successfully reversed epigenetic gene silencing of the STAT1 tumor suppressor in aggressive human prostate cancer cells, outperforming both Paclitaxel and Rapamycin.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The findings suggest Telomir-1 could restore i...